Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic
Identifieur interne : 000013 ( Main/Exploration ); précédent : 000012; suivant : 000014Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic
Auteurs : Margarita Pondal [Canada] ; Connie Marras [Canada] ; Janis Miyasaki [Canada] ; Elena Moro [Canada] ; Melissa J. Armstrong [Canada] ; Antonio P. Strafella [Canada] ; Binit B. Shah [Canada] ; Susan Fox [Canada] ; L K Prashanth [Canada] ; Nicolas Phielipp [Canada] ; Anthony E. Lang [Canada]Source :
- Journal of Neurology, Neurosurgery & Psychiatry [ 0022-3050 ] ; 2013-02.
Abstract
Background Recently, symptoms similar to addictive drug withdrawal have been reported in a structured longitudinal study of patients with idiopathic Parkinson's Disease (PD) withdrawing from dopamine agonists (DA): the dopamine agonist withdrawal syndrome (DAWS). Objectives The objective of this study was to establish the frequency, predictors, and outcomes of DAWS in a movement disorders clinic. Methods We conducted a retrospective chart review of a sample of patients with a clinical diagnosis of PD treated with DA in whom withdrawal or attempted withdrawal of DA was carried out because of adverse effects, or for any other reason. Out of 487 PD patient charts reviewed, 84 were withdrawn from the agonists and were evaluable. Results Thirteen patients (15.5%) met criteria for DAWS (DAWS+) and 71 did not (DAWS−). DAWS developed upon withdrawal from pergolide, pramipexole and ropinirole, and did not respond to levodopa. DAWS outcomes included recovery in less than 6 months in 61%, in more than a year in 23%, and an inability to discontinue DA in 15% of patients. Development of impulse control disorders was the reason for DA withdrawal in all DAWS+, but only in 41% of DAWS− patients (p<0.0001). DAWS+ and DAWS− patients did not differ in other variables. Conclusion DAWS is a disabling complication of DA use. Critical features of the syndrome are the strong link with impulse control disorders, possibly the independence of DA dosage and type, and the resistance to treatment, including levodopa. Further studies are required to characterise those at risk as well as to define an effective treatment.
Url:
DOI: 10.1136/jnnp-2012-302684
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic</title><author><name sortKey="Pondal, Margarita" sort="Pondal, Margarita" uniqKey="Pondal M" first="Margarita" last="Pondal">Margarita Pondal</name></author><author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name></author><author><name sortKey="Miyasaki, Janis" sort="Miyasaki, Janis" uniqKey="Miyasaki J" first="Janis" last="Miyasaki">Janis Miyasaki</name></author><author><name sortKey="Moro, Elena" sort="Moro, Elena" uniqKey="Moro E" first="Elena" last="Moro">Elena Moro</name></author><author><name sortKey="Armstrong, Melissa J" sort="Armstrong, Melissa J" uniqKey="Armstrong M" first="Melissa J" last="Armstrong">Melissa J. Armstrong</name></author><author><name sortKey="Strafella, Antonio P" sort="Strafella, Antonio P" uniqKey="Strafella A" first="Antonio P" last="Strafella">Antonio P. Strafella</name></author><author><name sortKey="Shah, Binit B" sort="Shah, Binit B" uniqKey="Shah B" first="Binit B" last="Shah">Binit B. Shah</name></author><author><name sortKey="Fox, Susan" sort="Fox, Susan" uniqKey="Fox S" first="Susan" last="Fox">Susan Fox</name></author><author><name sortKey="Prashanth, L K" sort="Prashanth, L K" uniqKey="Prashanth L" first="L K" last="Prashanth">L K Prashanth</name></author><author><name sortKey="Phielipp, Nicolas" sort="Phielipp, Nicolas" uniqKey="Phielipp N" first="Nicolas" last="Phielipp">Nicolas Phielipp</name></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1383EF35546E812F3C1739C01522FC673BDAF44B</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1136/jnnp-2012-302684</idno><idno type="url">https://api.istex.fr/document/1383EF35546E812F3C1739C01522FC673BDAF44B/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000E28</idno><idno type="wicri:Area/Main/Curation">000C61</idno><idno type="wicri:Area/Main/Exploration">000013</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic</title><author><name sortKey="Pondal, Margarita" sort="Pondal, Margarita" uniqKey="Pondal M" first="Margarita" last="Pondal">Margarita Pondal</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>The Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease, University Health Network and University of Toronto, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation><affiliation><wicri:noCountry code="no comma">E-mail: mpondals@gmail.com</wicri:noCountry></affiliation></author><author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>The Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease, University Health Network and University of Toronto, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Miyasaki, Janis" sort="Miyasaki, Janis" uniqKey="Miyasaki J" first="Janis" last="Miyasaki">Janis Miyasaki</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>The Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease, University Health Network and University of Toronto, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Moro, Elena" sort="Moro, Elena" uniqKey="Moro E" first="Elena" last="Moro">Elena Moro</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>The Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease, University Health Network and University of Toronto, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Armstrong, Melissa J" sort="Armstrong, Melissa J" uniqKey="Armstrong M" first="Melissa J" last="Armstrong">Melissa J. Armstrong</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>The Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease, University Health Network and University of Toronto, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Strafella, Antonio P" sort="Strafella, Antonio P" uniqKey="Strafella A" first="Antonio P" last="Strafella">Antonio P. Strafella</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>The Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease, University Health Network and University of Toronto, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Shah, Binit B" sort="Shah, Binit B" uniqKey="Shah B" first="Binit B" last="Shah">Binit B. Shah</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>The Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease, University Health Network and University of Toronto, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Fox, Susan" sort="Fox, Susan" uniqKey="Fox S" first="Susan" last="Fox">Susan Fox</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>The Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease, University Health Network and University of Toronto, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Prashanth, L K" sort="Prashanth, L K" uniqKey="Prashanth L" first="L K" last="Prashanth">L K Prashanth</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>The Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease, University Health Network and University of Toronto, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Phielipp, Nicolas" sort="Phielipp, Nicolas" uniqKey="Phielipp N" first="Nicolas" last="Phielipp">Nicolas Phielipp</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>The Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease, University Health Network and University of Toronto, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>The Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease, University Health Network and University of Toronto, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neurology, Neurosurgery & Psychiatry</title><title level="j" type="abbrev">J Neurol Neurosurg Psychiatry</title><idno type="ISSN">0022-3050</idno><idno type="eISSN">1468-330X</idno><imprint><publisher>BMJ Publishing Group Ltd</publisher><date type="published" when="2013-02">2013-02</date><biblScope unit="volume">84</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="130">130</biblScope></imprint><idno type="ISSN">0022-3050</idno></series><idno type="istex">1383EF35546E812F3C1739C01522FC673BDAF44B</idno><idno type="DOI">10.1136/jnnp-2012-302684</idno><idno type="href">jnnp-84-130.pdf</idno><idno type="ArticleID">jnnp-2012-302684</idno><idno type="PMID">22933817</idno><idno type="Related-article-Href">10.1136/jnnp-2012-303570</idno><idno type="related-article-ID">RA1</idno><idno type="local">jnnp;84/2/130</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-3050</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Background Recently, symptoms similar to addictive drug withdrawal have been reported in a structured longitudinal study of patients with idiopathic Parkinson's Disease (PD) withdrawing from dopamine agonists (DA): the dopamine agonist withdrawal syndrome (DAWS). Objectives The objective of this study was to establish the frequency, predictors, and outcomes of DAWS in a movement disorders clinic. Methods We conducted a retrospective chart review of a sample of patients with a clinical diagnosis of PD treated with DA in whom withdrawal or attempted withdrawal of DA was carried out because of adverse effects, or for any other reason. Out of 487 PD patient charts reviewed, 84 were withdrawn from the agonists and were evaluable. Results Thirteen patients (15.5%) met criteria for DAWS (DAWS+) and 71 did not (DAWS−). DAWS developed upon withdrawal from pergolide, pramipexole and ropinirole, and did not respond to levodopa. DAWS outcomes included recovery in less than 6 months in 61%, in more than a year in 23%, and an inability to discontinue DA in 15% of patients. Development of impulse control disorders was the reason for DA withdrawal in all DAWS+, but only in 41% of DAWS− patients (p<0.0001). DAWS+ and DAWS− patients did not differ in other variables. Conclusion DAWS is a disabling complication of DA use. Critical features of the syndrome are the strong link with impulse control disorders, possibly the independence of DA dosage and type, and the resistance to treatment, including levodopa. Further studies are required to characterise those at risk as well as to define an effective treatment.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Pondal, Margarita" sort="Pondal, Margarita" uniqKey="Pondal M" first="Margarita" last="Pondal">Margarita Pondal</name></noRegion><name sortKey="Armstrong, Melissa J" sort="Armstrong, Melissa J" uniqKey="Armstrong M" first="Melissa J" last="Armstrong">Melissa J. Armstrong</name><name sortKey="Fox, Susan" sort="Fox, Susan" uniqKey="Fox S" first="Susan" last="Fox">Susan Fox</name><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name><name sortKey="Miyasaki, Janis" sort="Miyasaki, Janis" uniqKey="Miyasaki J" first="Janis" last="Miyasaki">Janis Miyasaki</name><name sortKey="Moro, Elena" sort="Moro, Elena" uniqKey="Moro E" first="Elena" last="Moro">Elena Moro</name><name sortKey="Phielipp, Nicolas" sort="Phielipp, Nicolas" uniqKey="Phielipp N" first="Nicolas" last="Phielipp">Nicolas Phielipp</name><name sortKey="Prashanth, L K" sort="Prashanth, L K" uniqKey="Prashanth L" first="L K" last="Prashanth">L K Prashanth</name><name sortKey="Shah, Binit B" sort="Shah, Binit B" uniqKey="Shah B" first="Binit B" last="Shah">Binit B. Shah</name><name sortKey="Strafella, Antonio P" sort="Strafella, Antonio P" uniqKey="Strafella A" first="Antonio P" last="Strafella">Antonio P. Strafella</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000013 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000013 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:1383EF35546E812F3C1739C01522FC673BDAF44B
|texte= Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic
}}
| This area was generated with Dilib version V0.6.23. |  |